Tag: Bispecific antibody

The FDA granted accelerated approval to elranatamab (Elrexfio) in August 2023, making it a new, “off-the-shelf” treatment option for certain adults with heavily pretreated relapsed or refractory multiple myeloma. This innovative immunotherapy, part of a new class of bispecific T-cell engagers, provides a vital alternative for patients whose cancer has progressed after multiple prior therapies.

In non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), rilvegostomig has demonstrated an objective response rate (ORR) of 61.8% [1.5.6]. This article explores the question: What is rilvegostomig and its role in modern oncology?

In a clinical study published in *Cancer Discovery*, 49% of heavily pretreated patients with metastatic castration-resistant prostate cancer experienced a significant reduction in prostate-specific antigen (PSA) levels with the experimental immunotherapy Xaluritamig. This article explores this promising new treatment strategy and its role in oncology.